
We move at the speed of patient need. We exist to bring meaningful medicines to people living with genetic conditions. $BBIO
Palo Alto, California
Joined January 2021
- Tweets1.1K
- Following165
- Followers2.1K
- Likes112
We presented new ATTR-CM data at @American_Heart #AHA2026 and @ISA_Amyloidosis #ISA2026. Press release: bit.ly/4iIhBLz
Every minute matters. Today we’re launching The State of Impatience: an honest look at the assumptions we’re questioning, the tensions we’re living with, and where we’re still falling short. bit.ly/4z1Kl6H
4
247
“I don’t think of myself as a caregiver. I am her husband.” 32+ years in, Dave says he’d still choose Tara, who lives with LGMD, all over again. In sickness and in health. ❤️ #CaregiverAwarenessMonth #LGMD bit.ly/4sQP49Z
After 23 years in the U.S. #Army, Jimmy got a diagnosis at 62 that explained decades of symptoms: ADH1. Now he’s urging families to talk openly about health history. “ADH1 is something that doesn’t need to be silenced.” Read more of Jimmy’s Story: bit.ly/4BTxoi3
3
221
We will share 28 abstracts, including 12 posters on new analyses focused on ATTR-CM at @ISA_Amyloidosis (#ISA2026). These posters will include findings on kidney function, real-world outcomes and first-line treatment patterns. Learn more bit.ly/4t2LBW9
Two years running: BridgeBio is
@BioSpace’s #1 Best Place to Work. 🏆 Thank you to our team for building a culture rooted in one question: “What’s best for the patient?”
6
321
How do you measure a disease you can’t see? Stabilizers raise blood TTR. Knockdown agents lower it. Our scientists built a model of ATTR-CM whose core output, monomer efflux, puts both on one scale.
Read more: bit.ly/3X5keOW
We’ll be at two healthcare investor conferences in the coming weeks, with fireside chats at @Jefferies in London on 11/16, Evercore ISI in Miami on 11/30, @Citi in Miami on 12/1, and @Piper_Sandler in NYC on 12/2. More info: bit.ly/4iwHU60
4
321
Our CMO of Skeletal Dysplasias, Daniela Rogoff, M.D., Ph.D., was featured in @RareRevolutionM as part of Women in RARE, highlighting her career in #raredisease drug development and her commitment to making a meaningful difference for patients and families. We're grateful to have leaders like Daniela at BridgeBio who bring passion, scientific expertise and a patient-first perspective to everything they do. Read the full feature: rarerevolutionmagazine.com/r…
5
291
How can regulation keep pace with medical innovation?
Our Chief Regulatory Affairs Officer will join fellow panelists at the @MilkenInstitute #MIHealth Summit to explore evolving regulatory approaches, emerging technologies and global alignment. We look forward to Adora lending her expertise to this important conversation.
3
233
Early diagnosis is critical in limb-girdle muscular dystrophy (LGMD). Timely subtype confirmation via genetic testing may help inform management and anticipate complications, including the cardiac and respiratory involvement seen in LGMD2I/R9.
Jen put her career on hold to care for her son Mason, who lives with ADH1. “It was an unexpected sacrifice, but…seeing him thrive has been the most important and deeply rewarding work of my life.” Read more about Jen's story in honor of #CaregiverAwarenessMonth: bit.ly/4sQP49Z
2
274
“There are so many kids and so many families who fought for this for so long. Generations.” – Lee and Lori Greenwood, parents to Noa. Noa is one of more than 30 million Americans living with a rare disease. Behind that number are families still waiting. Watch the full video on our Insights page: bit.ly/4z9U5fL
5
355
BridgeBio will share three posters and two moderated posters on ATTR-CM at #AHA26 in Chicago (Nov. 6–9), including new ATTRibute-CM analyses on heart failure events and CV hospitalizations. Schedule: bit.ly/4sA40co
Heading to Chicago for #ScientificSessions26?
Add the BridgeBio Medical Theater to your AHA schedule to hear leading experts discuss patient management across the #ATTRCM journey and share firsthand perspectives on the evolving #ATTRCM treatment landscape.
Saturday, Nov 7 at 9:30 AM CT in Learning Studio 3.
Today, we shared our financial results for the third quarter and will host a conference call and webcast to discuss today at 4:30 pm ET. Read the full updates here: bit.ly/3UtyVKX
3
358
“It's very risky to invest in one drug because of that binary outcome. But what if we invested in, I don't know, 150 of them all at the same time?” – Andrew Lo, Ph.D., Massachusetts Institute of Technology. Noa is one of more than 30 million Americans living with a rare disease. Behind that number are families still waiting. Watch the full video on our Insights page: bit.ly/4z9U5fL
1
259
For people living with chronic #hypoparathyroidism considering a #clinicaltrial can also mean thinking about visits, travel, and everyday responsibilities. Here, we share where RECLAIM-HP Study activities may take place and the support available for eligible costs related to study visits.
3
271
Liz has been her husband Art's care partner since his diagnosis of ATTR-CM. This #WorldAmyloidosisDay, we're recognizing the people who notice what goes unsaid.
1
4
352
We will report Q3 2026 financial results and a business update after market close Thurs, Oct 29. Conference call at 4:30pm ET same day. Details: bit.ly/488BVPY
3
296
















